Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine · CARLISLE, PA · NPI 1982025631
Verified facts
CMS Open Payments records show Krishna Chalapathi Nemani, M.D. received $120.00 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $120.00 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $120.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 72 |
| Furosemide | Furosemide | 288 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 48 |
| Eliquis | Apixaban | 248 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 42 |
| Potassium Chloride | Potassium Chloride | 218 | 45 |
| Sertraline Hcl | Sertraline Hcl | 186 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 44 |
| Lisinopril | Lisinopril | 166 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 29 |
| Gabapentin | Gabapentin | 141 | 28 |
| Mirtazapine | Mirtazapine | 138 | 23 |
| Levetiracetam | Levetiracetam | 136 | 15 |
| Losartan Potassium | Losartan Potassium | 124 | 19 |
| Omeprazole | Omeprazole | 122 | 25 |
| Bumetanide | Bumetanide | 112 | 16 |
| Trazodone Hcl | Trazodone Hcl | 111 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 18 |
| Donepezil Hcl | Donepezil Hcl | 106 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 24 |
| Memantine Hcl | Memantine Hcl | 100 | 15 |
| Jardiance | Empagliflozin | 98 | 13 |
| Allopurinol | Allopurinol | 96 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 94 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 19 |
| Warfarin Sodium | Warfarin Sodium | 79 | suppressed |
| Carvedilol | Carvedilol | 71 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 20 |
| Buspirone Hcl | Buspirone Hcl | 68 | 19 |
| Spironolactone | Spironolactone | 66 | 15 |
| Risperidone | Risperidone | 64 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 12 |
| Famotidine | Famotidine | 59 | 15 |
| Metformin Hcl | Metformin Hcl | 59 | 16 |
| Latanoprost | Latanoprost | 54 | 13 |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Rexulti | Brexpiprazole | 45 | suppressed |
| Finasteride | Finasteride | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Simvastatin | Simvastatin | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Timolol Maleate | Timolol Maleate | 33 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 26 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 31 | 31 |
| Tramadol Hcl | Tramadol Hcl | 31 | 11 |
| Repaglinide | Repaglinide | 30 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Prednisone | Prednisone | 26 | 11 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 21 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 11 |
| Atenolol | Atenolol | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Nicardipine Hcl | Nicardipine Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | 11 |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Epogen | Epoetin Alfa | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Azithromycin | Azithromycin | 12 | 11 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $120.00 · 1 records | Novo Nordisk Inc | Ozempic | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error